However, studies carried out in R/R AML patients receiving adoptive NK cell therapy with haploidentical cells showed that systemic IL-15 administration resulted in reduced clinical activity compared with IL-2, through a mechanism related to the promotion of recipient CD8 T-cell activation, accelerating donor NK cell rejection [80]. The gene discussed is IL15; the disease is acute myeloid leukemia.